Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

baxter healthcare (malaysia) sdn. bhd. - sodium lactate; l-isoleucine usp; l-leucine usp; l-phenylalanine usp; l-threonine usp; l-tryptophan usp; l-histidine usp; l-proline usp; l-serine usp; l-valine usp; l-tyrosine usp; l-methionine usp; l-alanine usp; l-arginine usp; l-lysine hci usp; calcium chloride dihydrate usp; sodium chloride, usp; glycine, usp; magnesium chloride hexahydrate usp -

Malta - English - Medicines Authority

baxter healthcare limited caxton way, thetford, norfolk ip24 3se, united kingdom - calcium chloride, dihydrate, phenylalanine, histidine, arginine, threonine, tryptophan, tyrosine, valine, glycine, methionine, isoleucine, lysine, magnesium chloride, hexahydrate, serine, proline, sodium chloride, sodium lactate - solution for peritoneal dialysis - calcium chloride dihydrate 184 mg/ml phenylalanine 570 mg/ml histidine 714 mg/ml arginine 1071 mg/ml alanine 951 mg/ml threonine 646 mg/ml tryptophan 270 mg/ml tyrosine 300 mg/ml valine 1393 mg/ml glycine 510 mg/ml methionine 850 mg/ml isoleucine 850 mg/ml lysine 955 mg/ml magnesium chloride hexahydrate 51 mg/ml serine 510 mg/ml leucine 1020 mg/ml proline 595 mg/ml sodium chloride 5380 mg/ml sodium lactate 4480 mg/ml - blood substitutes and perfusion solutions

United States - English - NLM (National Library of Medicine)

epm packaging inc - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j) - acetaminophen 300 mg - codeine-containing products are contraindicated for postoperative pain management in children who have undergone tonsillectomy and/or adenoidectomy. this product should not be administered to patients who have previously exhibited hypersensitivity to codeine or acetaminophen.

United States - English - NLM (National Library of Medicine)

stat rx usa llc - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), butalbital (unii: khs0az4jvk) (butalbital - unii:khs0az4jvk), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e) - acetaminophen 325 mg - butalbital, acetaminophen and caffeine tablets are indicated for the relief of the symptom complex of tension (or muscle contraction) headache. evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent headaches is unavailable. caution in this regard is required because butalbital is habit-forming and potentially abusable. this product is contraindicated under the following conditions: - hypersensitivity or intolerance to any component of this product. - patients with porphyria. abuse and dependence: butalbital: barbiturates may be habit-forming: tolerance, psychological dependence, and physical dependence may occur especially following prolonged use of high doses of barbiturates. the average daily dose for the barbiturate addict is usually about 1500 mg. as tolerance to barbiturates develops, the amount needed to maintain the same level of intoxication increases; tolerance to a fatal dosage, however, does not increase more than two-fold. as thi

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 500 mg - tablet, enteric coated - excipient ingredients: hyprolose; calcium silicate; amaranth aluminium lake; titanium dioxide; polyvinyl acetate phthalate; diethyl phthalate; stearic acid; purified talc; povidone; hypromellose; magnesium stearate; macrogol 6000; indigo carmine aluminium lake; citric acid monohydrate - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 200 mg - tablet, enteric coated - excipient ingredients: citric acid monohydrate; polyvinyl acetate phthalate; indigo carmine aluminium lake; hyprolose; magnesium stearate; povidone; stearic acid; amaranth aluminium lake; diethyl phthalate; purified talc; macrogol 6000; calcium silicate; hypromellose; titanium dioxide - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - alanine, quantity: 16 g/l; glycylglutamine monohydrate, quantity: 30.27 g/l (equivalent: glutamine, qty 20 g); histidine, quantity: 6.8 g/l; methionine, quantity: 5.6 g/l; tryptophan, quantity: 1.9 g/l; threonine, quantity: 5.6 g/l; lysine acetate, quantity: 12.7 g/l (equivalent: glycine, qty 10.27 g; equivalent: lysine, qty 9 g); valine, quantity: 7.3 g/l; arginine, quantity: 11.3 g/l; glycyltyrosine dihydrate, quantity: 3.45 g/l (equivalent: tyrosine, qty 2.28 g; equivalent: glycine, qty 0.94 g); serine, quantity: 4.5 g/l; proline, quantity: 6.8 g/l; glutamic acid, quantity: 5.6 g/l; leucine, quantity: 7.9 g/l; isoleucine, quantity: 5.6 g/l; aspartic acid, quantity: 3.4 g/l; phenylalanine, quantity: 5.85 g/l - injection, intravenous infusion - excipient ingredients: water for injections; citric acid - glamin provides amino acids as part of parenteral nutrition therapy, when oral or enteral nutrition is impossible, insufficient or contraindicated especially in patients with a moderate or severe catabolic status.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - proline, quantity: 6.8 g/l; isoleucine, quantity: 5.6 g/l; methionine, quantity: 5.6 g/l; lysine acetate, quantity: 12.7 g/l (equivalent: lysine, qty 9 g; equivalent: glycine, qty 10.27 g); serine, quantity: 4.5 g/l; glycylglutamine monohydrate, quantity: 30.27 g/l (equivalent: glycine, qty 10.27 g; equivalent: glutamine, qty 20 g); alanine, quantity: 16 g/l; histidine, quantity: 6.8 g/l; glutamic acid, quantity: 5.6 g/l; tryptophan, quantity: 1.9 g/l; leucine, quantity: 7.9 g/l; valine, quantity: 7.3 g/l; aspartic acid, quantity: 3.4 g/l; phenylalanine, quantity: 5.85 g/l; glycyltyrosine dihydrate, quantity: 3.45 g/l (equivalent: tyrosine, qty 2.28 g; equivalent: glycine, qty 0.94 g); arginine, quantity: 11.3 g/l; threonine, quantity: 5.6 g/l - injection, intravenous infusion - excipient ingredients: citric acid; water for injections - glamin provides amino acids as part of parenteral nutrition therapy, when oral or enteral nutrition is impossible, insufficient or contraindicated especially in patients with a moderate or severe catabolic status.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - glycyltyrosine dihydrate, quantity: 3.45 g/l (equivalent: tyrosine, qty 2.28 g; equivalent: glycine, qty 0.94 g); histidine, quantity: 6.8 g/l; alanine, quantity: 16 g/l; lysine acetate, quantity: 12.7 g/l (equivalent: lysine, qty 9 g; equivalent: glycine, qty 10.27 g); glycylglutamine monohydrate, quantity: 30.27 g/l (equivalent: glutamine, qty 20 g; equivalent: glycine, qty 10.27 g); glutamic acid, quantity: 5.6 g/l; phenylalanine, quantity: 5.85 g/l; valine, quantity: 7.3 g/l; leucine, quantity: 7.9 g/l; tryptophan, quantity: 1.9 g/l; methionine, quantity: 5.6 g/l; isoleucine, quantity: 5.6 g/l; serine, quantity: 4.5 g/l; proline, quantity: 6.8 g/l; arginine, quantity: 11.3 g/l; threonine, quantity: 5.6 g/l; aspartic acid, quantity: 3.4 g/l - injection, intravenous infusion - excipient ingredients: citric acid; water for injections - glamin provides amino acids as part of parenteral nutrition therapy, when oral or enteral nutrition is impossible, insufficient or contraindicated especially in patients with a moderate or severe catabolic status.

Malta - English - Medicines Authority

baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - calcium chloride, dihydrate, phenylalanine, histidine, arginine, threonine, tryptophan, tyrosine, valine, glycine, methionine, isoleucine, lysine hydrochloride, magnesium chloride, hexahydrate, serine, proline, sodium chloride, sodium lactate - solution for peritoneal dialysis - tryptophan 270 mg/l calcium chloride dihydrate 184 mg/l arginine 1071 mg/l alanine 951 mg/l phenylalanine 570 mg/l histidine 714 mg/l threonine 646 mg/l glycine 510 mg/l methionine 850 mg/l isoleucine 850 mg/l lysine hydrochloride 955 mg/l magnesium chloride hexahydrate 51 mg/l serine 510 mg/l leucine 1020 mg/l proline 595 mg/l sodium chloride 5380 mg/l sodium lactate 4480 mg/l tyrosine 300 mg/l valine 1393 mg/l - blood substitutes and perfusion solutions